Sign in
TerminatedPhase 1

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Key facts

Who runs it
University of Chicago
Where
Chicago, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
50 people enrolled
Started
24 Jan 2023
Ended
16 Nov 2024
Type of study
Interventional, 4 groups
Treatments tested
  • Abiraterone Oral Tablet
  • Prednisone tablet
  • Drug Dairy/Log
  • Low-fat meal
Record updated
3 October 2025
Why it stopped
Closed by PI due to not meeting primary endpoint

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Histologically or cytologically confirmed prostate cancer with plans to initiate abiraterone acetate
  • Have never received prior abiraterone or other androgen receptor modulators, including enzalutamide, apalutamide, or darolutamide
  • Must have a baseline DHEA-S level of >20 mg/dL (in order to adequately assess DHEA-S response)
  • A minimum washout of 28 days for any other anticancer therapy other than medical or surgical castration, prior to first dose of study drug is required
  • Any other radiotherapy or radionuclide require 28-day washout prior to first dose of study drug
  • Denosumab or zoledronic acid are allowed
  • Eastern Cooperative Oncology Group performance status ≤ 2 (Appendix A)
  • Participants must have normal hepatic function as defined by clinical lab values set by the study doctor/research team
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Therapy with other hormonal therapy, including any dose of megestrol acetate (Megace), finasteride (Proscar), dutasteride (Avodart), or any herbal product known to decrease Prostate-Specific Antigen levels or any systemic corticosteroid (other than prednisone ≤10mg/day) within 4 weeks prior to first dose of study drug
  • Taking other medications or drugs with strong inhibitors or inducers of CYP3A4 (See Section 8.12 below for list of strong inhibitor or inducers) due to concerning possible drug-drug interactions with abiraterone
  • Serious intercurrent infections or non-malignant medical illnesses that are uncontrolled
  • Active psychiatric illness/social situations that would limit compliance with protocol requirements
  • Serious heart issues/congestive heart failure as assessed by New York Heart Association's definition of class II, class III, or IV congestive heart failure
  • Serum K+ < 3.5 mmoL/L. Patients with a K+ < 3.5 mmoL/L are required to have a documented subsequent K+ >3.5 prior to enrollment to be eligible
  • Inability to swallow capsules or known gastrointestinal malabsorption
  • Blood pressure that is not controlled despite > 2 oral agents (SBP >160 and DBP >90 documented during the screening period with no subsequent blood pressure readings <160/100)

Where in United States

  • University of Chicago Medicine-Comprehensive Cancer CenterChicago, United States

About the trial

What the trial wants to find out

Doctors leading this study plan to collect new information about the lowest effective dose of abiraterone acetate in study participants with prostate cancer who are taking abiraterone in combination with prednisone for the first time. The duration of this study will be about 3 months (12 weeks). How long you stay on abiraterone, and at what dose after completion of the 12 weeks of study drug administration, will be up to you and your treating physician.

The 4 groups in the trial

  • Group 1: Dose Regimen 1Treatment being tested

    You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive: \- Abiraterone 500 mg and prednisone 5mg with a low-fat meal every other day. You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log. You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary.

    Treatment: Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, and Low-fat meal

  • Group 2: Dose Regimen 2Treatment being tested

    You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive: \- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1, day 3, day 5 of every week You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log. You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary.

    Treatment: Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, and Low-fat meal

  • Group 3: Dose Regimen 3Treatment being tested

    You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive: \- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 and day 4 of every week You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log. You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary.

    Treatment: Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, and Low-fat meal

  • Group 4: Dose Regimen 4Treatment being tested

    You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive: \- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 of every week You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log. You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary.

    Treatment: Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, and Low-fat meal

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Abiraterone Dose De-Escalation Study: A Prospective Study Evaluating Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
Record updated
3 October 2025